...
首页> 外文期刊>Frontiers in Immunology >Monocyte Chemotactic Protein 1 in Plasma from Soluble Leishmania Antigen-Stimulated Whole Blood as a Potential Biomarker of the Cellular Immune Response to Leishmania infantum
【24h】

Monocyte Chemotactic Protein 1 in Plasma from Soluble Leishmania Antigen-Stimulated Whole Blood as a Potential Biomarker of the Cellular Immune Response to Leishmania infantum

机译:可溶性利什曼原虫抗原刺激的全血血浆中的单核细胞趋化蛋白1,作为对婴儿利什曼原虫的细胞免疫反应的潜在生物标志物

获取原文
           

摘要

New biomarkers are needed to identify asymptomatic Leishmania infection as well as immunity following vaccination or treatment. With the aim of finding a robust biomarker to assess an effective cellular immune response, monocyte chemotactic protein 1 (MCP-1) was examined in plasma from soluble Leishmania antigen (SLA)-stimulated whole blood collected from subjects living in a Leishmania infantum -endemic area. MCP-1, expressed 110 times more strongly than IL-2, identified 87.5% of asymptomatic subjects and verified some asymptomatic subjects close to the cutoff. MCP-1 was also significantly elevated in all patients cured of visceral leishmaniasis (VL), unlike IL-2, indicating the specific memory response generated against Leishmania . These results show MCP-1 to be a robust candidate biomarker of immunity that could be used as a marker of cure and to both select and follow the population in vaccine phase I–III human clinical trials with developed rapid, easy-to-use field tools.
机译:需要新的生物标记物来鉴定无症状的利什曼原虫感染以及疫苗接种或治疗后的免疫力。为了找到一个强大的生物标记物来评估有效的细胞免疫应答,对血浆中的单核细胞趋化蛋白1(MCP-1)进行了检测,该血浆来自可溶性利什曼原虫抗原(SLA)刺激的全血,该血液来自生活在婴儿利什曼原虫流行的受试者中区。 MCP-1的表达强度是IL-2的110倍,可识别出87.5%的无症状受试者,并证实了一些接近临界值的无症状受试者。与IL-2不同,在所有内脏利什曼病(VL)治愈的患者中MCP-1也显着升高,表明针对利什曼原虫产生了特异性记忆反应。这些结果表明,MCP-1是免疫力的强大候选生物标志物,可以用作治疗的标志物,并且可以在I–III疫苗阶段的人类临床试验中选择和关注人群,并开发了快速,易于使用的领域工具。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号